Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin's lymphoma.
In order to analyze the clinical relevance of the pharmacokinetic interactions between vinblastine and antiretrovirals described in literature, we evaluated all HIV-infected patients with Hodgkin's lymphoma treated with vinblastine-containing regimens and combination antiretroviral therapy, in a single clinical center. The use of protease inhibitors was independently associated with WHO grade III-IV neutropenia. Moreover, an inverse correlation between dosage of ritonavir and mean nadir neutrophil count was found. The concomitant administration of vinblastine-containing chemotherapy regimens with protease inhibitors can lead to higher levels of neutropenia than those of different classes of drugs such as nonnucleoside reverse transcriptase inhibitors or integrase inhibitors.
Cingolani
Antonella
A
Institute of Infectious Diseases, Catholic University, Rome, Italy. a.cingolani@rm.unicatt.it
Torti
Lorenza
L
Pinnetti
Carmela
C
de Gaetano Donati
Katleen
K
Murri
Rita
R
Tacconelli
Evelina
E
Larocca
Luigi Maria
LM
Teofili
Luciana
L
D000328:Adult; D000368:Aged; D004347:Drug Interactions; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D017320:HIV Protease Inhibitors / Q000008:administration & dosage* / Q000493:pharmacokinetics; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D019438:Ritonavir / Q000008:administration & dosage* / Q000493:pharmacokinetics; D014747:Vinblastine / Q000008:administration & dosage* / Q000493:pharmacokinetics*
D017320:HIV Protease Inhibitors; D014747:Vinblastine; D019438:Ritonavir